Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
NIFTY200 Alpha 30
NIFTY200 Alpha 30 Performance
Day's Range
Low
₹25,598.25
High
₹25,851.70
52 Week Range
Low
₹21,846.40
High
₹26,553.90
| Previous Close | ₹25,615.80 |
|---|---|
| Day's Range | ₹25,598.25 - ₹25,851.70 |
| Open | ₹25,711.45 |
| 52 Week Range | ₹21,846.40 - ₹26,553.90 |
| Volume | 10,85,50,369 |
NIFTY200 Alpha 30 Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Bharat Electronics Ltd. | 407.10 |  -2.80 (-0.68%) |
Capital Goods |
| State Bank Of India | 986.55 |  7.30 (0.75%) |
Bank |
| Max Financial Services Ltd. | 1614.50 | 33.00 (2.09%) |
Finance |
| Vedanta Ltd. | 317.70 | -9.80 (-2.99%) |
Non - Ferrous Metals |
| The Federal Bank Ltd. | 299.80 | -0.30 (-0.10%) |
Bank |
| Ashok Leyland Ltd. | 145.42 | 0.98 (0.68%) |
Automobile & Ancillaries |
| Cummins India Ltd. | 5815.50 | 28.00 (0.48%) |
Automobile & Ancillaries |
| Bharat Forge Ltd. | 1942.70 | 5.20 (0.27%) |
Automobile & Ancillaries |
| Eicher Motors Ltd. | 7122.00 | 12.00 (0.17%) |
Automobile & Ancillaries |
| Shriram Finance Ltd. | 928.70 | 12.90 (1.41%) |
Finance |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 23429.3 | 26373.20 | 22182.55 |
| Nifty IT | 29090.6 | 40301.40 | 27078.00 |
| Nifty Next 50 | 70431.4 | 72442.15 | 59896.10 |
| NIFTY50 USD Index | 8516.25 | 10443.40 | 8132.40 |
| Nifty Bank | 54607.6 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 61172.8 | 62907.50 | 52032.85 |
| Nifty 500 | 22546.65 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 17330.65 | 17859.10 | 14804.55 |
| Nifty 100 | 24465.6 | 26975.15 | 22720.45 |
| Nifty FMCG | 48205.8 | 58485.05 | 45334.15 |
Latest News
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market3 achieved annual sales of approximately $15.2 million*. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about transcript of earnings call
Further to its letter dated May 23, 2026 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, Glenmark Pharmaceuticals has informed that it enclosed the transcript of the Earnings call held on Monday, June 01, 2026 for the fourth quarter and year ended March 31, 2026 has been uploaded on the Company’s website.
The above information is a part of company’s filings submitted to BSE.
Cummins India informs about analyst meet
One 97 Communications informs about allotment of ESOP
Ashok Leyland informs about monthly business updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of NT200ALP30 index is ₹25791.55 as of 2026-06-05.
The total volume of NT200ALP30 index is 108550369.00 as of 2026-06-05.
The percentage change in value of NT200ALP30 index is 0.69% as of 2026-06-05.
The absolute increase in NT200ALP30 index value since the previous trading day is ₹175.75 as of 2026-06-05.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
